person · Reporting owner
Klinger Shannon Thyme
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Legal Officer | September 04, 2026 | September 08, 2026 |
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | January 05, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,340 |
Ending reported balance
After 2026-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-04 · Exercise / conversion · Acquired 11,797 · Balance 87,044 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-09-04 · Tax withholding · Disposed 5,704 · Balance 81,340 F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 106,179 |
Reported balance
After 2026-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-04 · Exercise / conversion · Disposed 11,797 · Balance 106,179 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Rafael Holdings, Inc.
Report date January 05, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 5,412 |
Reported balance
After 2022-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-05 · Grant · Acquired 5,412 · Balance 5,412 F1: Grant of Restricted Stock that vests in full immediately. F2: Represents the average closing price of the Issuer's Class B common stock during December 2021. F3: Consists of fully vested shares of Restricted Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock that vests in full immediately.
F2: Represents the average closing price of the Issuer's Class B common stock during December 2021.
F3: Consists of fully vested shares of Restricted Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 8, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000169 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,179 Underlying: Common Stock · 11,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,704 | $148.87 | $849,154.48 |
DisclosureSEC source: 0001682852-26-000169 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,340 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000169 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · derivative · entry 6 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,661 Underlying: Common Stock · 2,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,471 | $0.00 Strike: $30.96 | $0.00 |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,716 Underlying: Common Stock · 3,471 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,048 | $140.34 | $147,076.32 |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · nonDerivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,247 F3 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,471 | $139.95 | $485,766.45 |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,129 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 3,471 | $30.96 | $107,462.16 |
DisclosureSEC source: 0001682852-26-000167 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · derivative · entry 6 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 658 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 160 | $142.77 | $22,843.20 |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · nonDerivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,129 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,642 Underlying: Common Stock · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 375 | $149.66 | $56,122.50 |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,960 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| August 27, 2026 Filed Aug 31, 2026 20:37 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000157 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · derivative · entry 6 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,976 Underlying: Common Stock · 11,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,705 | $51.59 | $294,320.95 |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · nonDerivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,561 F3 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,471 | $0.00 Strike: $30.96 | $0.00 |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,187 Underlying: Common Stock · 3,471 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 3,471 | $50.00 | $173,550.00 |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,468 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 3,471 | $30.96 | $107,462.16 |
DisclosureSEC source: 0001682852-26-000119 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000113 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,827 Underlying: Common Stock · 2,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,047 | $47.19 | $49,407.93 |
DisclosureSEC source: 0001682852-26-000113 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,468 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000113 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · derivative · entry 6 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 987 Underlying: Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 159 | $47.61 | $7,569.99 |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · nonDerivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,350 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 773 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 374 | $47.03 | $17,589.22 |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,181 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 773 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000107 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000051 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,774 Underlying: Common Stock · 11,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 5,704 | $57.80 | $329,691.20 |
DisclosureSEC source: 0001682852-26-000051 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,782 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 21:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 11,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000051 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,885 | $0.00 Strike: $30.96 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 17 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,658 Underlying: Common Stock · 13,885 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. F10 · derivative.exercise_date: 25% of this option vested and became exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 13,885 | $52.29 | $726,046.65 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 10 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,689 F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 13,885 | $30.96 | $429,879.60 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 9 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 38,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 16 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,553 Underlying: Common Stock · 38,553 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F9 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F9 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 29,275 | $0.00 Strike: $53.57 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 15 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,275 Underlying: Common Stock · 29,275 shares Expires 2036-03-01 F8 · derivative.exercise_date: 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 8,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 14 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,992 Underlying: Common Stock · 8,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F7 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F7 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 13 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,189 Underlying: Common Stock · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F6 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 12 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,315 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · derivative · entry 11 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 4,189 | $51.71 | $216,613.19 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 8 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,689 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 8,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 7 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 375 | $51.71 | $19,391.25 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 6 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,215 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 160 | $51.71 | $8,273.60 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,816 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 113 | $51.71 | $5,843.23 |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,647 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:10 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001682852-26-000040 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.